No Data
Theratechnologies (THTX) Gets a Buy From JonesTrading
Theratechnologies Shareholders Elect Directors, Appoint Auditors
Theratechnologies Elects New Board Chair
Theratechnologies Reports on Its Annual Meeting of Shareholders
MONTREAL, May 09, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of
Express News | Theratechnologies Will Present Long-term Efficacy, Safety And Pharmacokinetic Data On The Use Of Its Lead Investigational TH1902 (Sudocetaxel Zendusortide), In Patients With Solid Tumors, At The American Society Of Clinical Oncology
Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (Sudocetaxel Zendusortide) in Solid Tumors at 2024 ASCO Meeting
First long-term data presentation from Parts 1 and 2 of the Phase 1 clinical trial of sudocetaxel zendusortide in solid tumors Part 3 of Phase 1 trial in advanced ovarian cancer is ongoing MONTREAL, May 02, 2024